{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:59:59Z","timestamp":1790449199535,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> With the widespread application of Immune checkpoint inhibitors (ICIs), it is important to explore the association between ICIs and cardiac arrhythmias and to characterize the clinical features of ICI-associated cardiac arrhythmias in real-world studies.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The purpose of this study was to characterize the main features of ICI-related cardiac arrhythmias.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> From January 2017 to June 2021, data in the Food and Drug Administration Adverse Event Reporting System (FAERS) database were retrieved to conduct the disproportionality analysis. For the ICI-related cardiac arrhythmia detection, signals were detected by reporting odds ratio (ROR) and information component (IC), calculated using two-by-two contingency tables The clinical characteristics of patients reported with ICI-related cardiac arrhythmias were compared between fatal and non-fatal groups, and the time to onset (TTO) following different ICI regimens was further investigated. Multivariate logistic regression was used to evaluate the association between concurrent cardiotoxicities and ICI-associated arrhythmias.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We identified a total of 1957 ICI\u2013associated cardiac arrhythmias reports which appeared to influence more men (64.44%) than women (30.76%), with a median age of 68 [interquartile range (IQR) 60\u201375] years. Cardiac arrhythmias were reported most often in patients with lung, pleura, thymus and heart cancers (38.02% of 1957 patients). Compared with the full database, ICIs were detected with pharmacovigilance of cardiac arrhythmias (ROR025 = 1.16, IC025 = 0.19). Anti-PD-1 and anti-PD-L1 monotherapies were found to be related to higher reporting of arrhythmias, corresponding to ROR025 = 1.03, IC025 = 0.06 and ROR025 = 1.27, IC025 = 0.29, respectively, with the exception of anti-CTLA-4 monotherapies (ROR025 = 0.57, IC025 = \u22121.21). The spectrum of arrhythmias induced by ICIs differed among therapeutic regimens. There was no significant difference in the onset time between monotherapy and combination regimen. Moreover, reports of ICI-associated arrhythmias were associated with other concurrent cardiotoxicity, including cardiac failure [ROR 2.61 (2.20\u20133.09)], coronary artery disorders [ROR 2.28 (1.83\u20132.85)], myocardial disorders [ROR 5.25 (4.44\u20136.22)], pericardial disorders [ROR 2.76 (2.09\u20133.64)] and cardiac valve disorders [ROR 3.21 (1.34\u20137.68)].<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> ICI monotherapy and combination therapy can lead to cardiac arrhythmias that can result in serious outcomes and tend to occur early. Our findings underscore the importance of early recognition and management of ICI-related cardiac arrhythmias.<\/jats:p>","DOI":"10.3389\/fphar.2022.986357","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:18:55Z","timestamp":1667539135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Feifei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/eurheartj\/ehab219","article-title":"Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis","volume":"42","author":"Alhumaid","year":"2021","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik","year":"2021","journal-title":"Clin. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e4869","DOI":"10.7759\/cureus.4869","article-title":"Nivolumab-induced third degree atrioventricular block in a patient with stage IV squamous cell lung carcinoma","volume":"11","author":"Bukamur","year":"2019","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cvr\/cvz025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.4022\/jafib.2461","article-title":"Incidence of cancer treatment induced arrhythmia associated with immune checkpoint inhibitors","volume":"13","author":"Joseph","year":"2021","journal-title":"J. Atr. Fibrillation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block Associated with pembrolizumab-induced acute myocarditis: The need for close cardiac monitoring","volume":"57","author":"Katsume","year":"2018","journal-title":"Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial toxicities associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: A retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neurooncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: A systematic review of the literature in an important emerging area","volume":"34","author":"Mir","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.revmed.2019.12.023","article-title":"Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review","volume":"41","author":"Prevel","year":"2020","journal-title":"Rev. Med. Interne"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/20009666.2021.1965708","article-title":"Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma","volume":"11","author":"Savarapu","year":"2021","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity: Current understanding on its mechanism, diagnosis and management","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.986357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:18:58Z","timestamp":1667539138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.986357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":29,"alternative-id":["10.3389\/fphar.2022.986357"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.986357","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"article-number":"986357"}}